Clinical Trial: Induction of Migraine Aura With Cilostazol

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: The Effect of the Selective PDE3 Inhibitor on Migraine With Aura Induction and Vascular Endothelial Function.

Brief Summary: In a double blind placebo-controlled cross-over study the effect of cilostazol on aura induction and endothelial response is tested in patient with migraine with aura.

Detailed Summary: Migraine with aura is associated to an increased risk of stroke. The mechanism behind such increased risk is not fully understood. Cilostazol induce headache and migraine in migraine patients and is used as secondary prevention of stroke. The effect on aura induction is not known. We investigate the aura inducing potential of cilostazol and associated changes in endothelial function.
Sponsor: Herlev Hospital

Current Primary Outcome: Aura [ Time Frame: 24 hours ]

Induction of aura reported by an aura diary for 24 hours post medication


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Migraine [ Time Frame: 24 hours ]
    Induction of headache resembling usual migraine attacks
  • Endothelial response [ Time Frame: 3 hours ]
    Measurement of endothelial response by Endopat2000 before and after administration of placebo and cilostazol


Original Secondary Outcome: Same as current

Information By: Herlev Hospital

Dates:
Date Received: September 26, 2014
Date Started: September 2014
Date Completion:
Last Updated: August 20, 2015
Last Verified: August 2015